What types of hematological tumors are Venexaclavin mainly used to treat?

Venetoclax is an oral small molecule drug that is mainly used to treat a variety of hematological malignancies, especially cancer types such as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and small lymphocytic lymphoma (SLL). It works by targeting the BCL-2 protein, one of the important factors in tumor cells that promotes survival.

In normal cells, BCL-2 protein helps maintain cell survival and prevent cells from self-destruction due to factors such as DNA damage. However, in some tumor cells, overexpression of BCL-2 allows tumor cells to evade natural cell death mechanisms and grow uncontrollably. Venetoclax binds to BCL-2 protein and inhibits its function, making tumor cells unable to escape death signals, ultimately leading to tumor cell death. This mechanism of action makes venetoclax an effective targeted drug for the treatment of BCL-2-dependent hematological tumors.

Veneclat is most commonly used to treat chronic lymphocytic leukemia (CLL), a common adult blood cancer that typically occurs in older adults. The main characteristic of CLL is the abnormal proliferation of B cells. By targeting the BCL-2 protein, venetoclax significantly reduces the viability of cancer cells and helps delay the progression of the disease, especially for patients who have developed resistance to traditional chemotherapy or other targeted therapies. Clinical data shows that venetoclax, when used in combination with other drugs (such as acalatinib), can significantly improve the treatment response rate and help patients achieve remission.

In addition, venetoclax has also demonstrated good efficacy in the treatment of acute myeloid leukemia (AML). AML is a highly aggressive and rapidly progressing hematological tumor. The conventional treatment plan is mostly chemotherapy. In some AML patients, venetoclax can be used in combination with chemotherapy drugs to enhance the tumor-killing effect of chemotherapy drugs. The introduction of venetoclax has improved the therapeutic response of AML patients, especially in those patients with high BCL-2 expression.

Reference materials:https://www.venclexta.com/